Insmed(US:INSM) Prnewswireยท2024-07-29 12:00Core Insights - Insmed Incorporated is set to release its second-quarter 2024 financial results on August 8, 2024, and will host a conference call for investors at 8:00 a.m. ET on the same day to discuss these results and provide a business update [4][2]. Company Overview - Insmed is a global biopharmaceutical company focused on transforming the lives of patients with serious and rare diseases. Its first commercial product is a first-in-disease therapy approved in Japan for a chronic lung disease [3]. - The company is advancing a robust pipeline of investigational therapies targeting serious unmet needs, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Additionally, Insmed is developing an early-stage research engine that includes technologies such as artificial intelligence-driven protein engineering, gene therapy, and protein manufacturing [3]. Conference Call Details - Interested parties can participate in the conference call by dialing (888) 210-2654 (U.S.) or (646) 960-0278 (international), referencing access code 7862189. The call will also be available via live webcast on the company's website [6][2]. - A replay of the conference call will be accessible approximately one hour after its completion until September 7, 2024, by dialing (800) 770-2030 (U.S.) or (609) 800-9909 (international) [1].